Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Verma · SciRah

Researcher profile · Semantic Scholar

S. Verma

Share profile

S. Verma — researcher profile on SciRah

h-index: 17
Works: 54
Citations: 1,786

Most-cited papers

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
J. Baselga, K. Gelmon, S. Verma, A. Wardley +8 more
2010Journal of Clinical Oncology661 citations Open access
Semantic Scholar
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
J. Connors, P. Klimo, G. Adams, B. Burns +12 more
1997Journal of Clinical Oncology154 citations
Semantic Scholar
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
H. Rugo, A. Stopeck, A. Joy, S. Chan +8 more
2011Journal of Clinical Oncology102 citations
Semantic Scholar
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group.
Kathleen I. Pritchard, Alexander H. G. Paterson, S. Fine, Nancy Paul +18 more
1997Journal of Clinical Oncology100 citations
Semantic Scholar
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Vanessa Bernstein, S. Ellard, S. Dent, Dong-Sheng Tu +15 more
2017Breast Cancer Research and Treatment91 citations
Semantic Scholar
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
D. Toppmeyer, A. Seidman, M. Pollak, C. Russell +7 more
2002Clinical Cancer Research78 citations
Semantic Scholar
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon
N. Wong, R. Buckman, M. Clemons, S. Verma +11 more
2010Journal of Clinical Oncology77 citations Open access
Semantic Scholar
A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)
H. Rugo, A. Stopeck, A. Joy, S. Chan +6 more
200744 citations
Semantic Scholar
A Randomized Phase II Study of Cisplatin Alone Versus Cisplatin Plus Disulfiram
S. Verma, D. Stewart, J. Maroun, R. Nair
1990American Journal of Clinical Oncology44 citations
Semantic Scholar
Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.
J. Cortes, J. Baselga, T. Petrella, K. Gelmon +6 more
2016Journal of Clinical Oncology43 citations
Semantic Scholar
Randomized placebo‐controlled trial of granulocyte‐macrophage colony‐stimulating‐factor support for dose‐intensive cyclophosphamide, etoposide, and cisplatin
J. Yau, James A. Neldhart, P. Triozzi, S. Verma +6 more
1996American journal of hematology/oncology36 citations Open access
Semantic Scholar
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma
D. Morris, V. Bramwell, R. Turcotte, A. Figueredo +4 more
2006Sarcoma34 citations Open access
Semantic Scholar
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
V. H. C. Bramwell, I. Quirt, D. Warr, S. Verma +3 more
1989Journal of the National Cancer Institute34 citations
Semantic Scholar
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
T. Vandenberg, Kathleen I. Pritchard, E. Eisenhauer, Maureen E. Trudeau +5 more
1993Journal of Clinical Oncology33 citations
Semantic Scholar
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
H. Au, K. Golmohammadi, T. Younis, S. Verma +3 more
2009Breast Cancer Research and Treatment25 citations
Semantic Scholar
Pharmacologic insights into the future of trastuzumab.
Brian Leyland-Jones, A. Arnold, K. Gelmon, S. Verma +5 more
2001Annals of Oncology23 citations Open access
Semantic Scholar
2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)
S. Chan, A. Stopeck, A. Joy, S. Verma +6 more
200719 citations
Semantic Scholar
Bioavailability and pharmacology of oral idarubicin
D. Stewart, D. Grewaal, R. M. Green, S. Verma +4 more
2004Cancer Chemotherapy and Pharmacology16 citations
Semantic Scholar
Phase I Study of the Combination of Disulfiram with Cisplatin
D. Stewart, S. Verma, J. Maroun
1987American Journal of Clinical Oncology16 citations
Semantic Scholar
Phase I clinical study of didemnin B
Jean A. Maroun, David J. Stewart, S. Verma, E. Eisenhauer
2004Investigational new drugs14 citations
Semantic Scholar
A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma
V. Bramwell, M. Blackstein, K. Bélanger, S. Verma +2 more
1998Sarcoma14 citations Open access
Semantic Scholar
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
D. Stewart, H. Hugenholtz, V. DaSilva, B. Benoit +4 more
1987Seminars in Oncology13 citations
Semantic Scholar
Phase I Study of Acivicin and Cisplatin in Non‐Small‐Cell Lung Cancer: A National Cancer Institute of Canada Study
J. Maroun, D. Stewart, S. Verma, W. Evans +1 more
1990American Journal of Clinical Oncology12 citations
Semantic Scholar
Phase I Study of Weekly Intravenous Administration of Menogaril to Adults with Solid Tumors
D. Stewart, J. Maroun, S. Verma, D. Perrault +1 more
1989American Journal of Clinical Oncology10 citations
Semantic Scholar
Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study
D. Stewart, L. Morgan, S. Verma, J. Maroun +1 more
2007Investigational new drugs9 citations
Semantic Scholar
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
J. Yau, Stanley Z. Gertler, John Hanson, S. Verma +8 more
2000American Journal of Clinical Oncology9 citations
Semantic Scholar
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
David J. Stewart, E. Eisenhauer, J. Skillings, K. Pritchard +5 more
1992Annals of Oncology9 citations Open access
Semantic Scholar
Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial
H. Burris, A. Chan, M. Campone, K. Blackwell +11 more
20176 citations
Semantic Scholar
Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non‐Hodgkin's lymphoma
J. Yau, C. Germond, S. Glück, C. Cripps +5 more
1998American journal of hematology/oncology6 citations Open access
Semantic Scholar
Phase I study of oral menogaril administered on a once weekly schedule
D. Stewart, S. Verma, J. Maroun, L. Robillard +1 more
1990Investigational new drugs6 citations
Semantic Scholar
Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study
D. Stewart, R. Goel, M. Cripps, S. Huan +2 more
2004Investigational new drugs5 citations
Semantic Scholar
Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.
Jean A. Maroun, David J. Stewart, S. Verma, E. Eisenhauer
1998Investigational new drugs5 citations
Semantic Scholar
848 Docetaxel (taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): A phase II trial
M. Blackstein, E. Eisenhauer, V. Bramwell, K. Bélanger +2 more
19955 citations
Semantic Scholar
Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials
J. Beck, P. Neven, F. Esteva, A. Bardia +9 more
2019Poster Session Abstracts4 citations
Semantic Scholar
Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics
F. André, S. Stemmer, G. Hortobagyi, H. Burris +16 more
20164 citations
Semantic Scholar
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma
J. Skillings, C. Cripps, E. Eisenhauer, J. Pater +2 more
1991Investigational new drugs4 citations
Semantic Scholar
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.
M. Cristofanilli, A. DeMichele, C. Giorgetti, D. Slamon +9 more
20173 citations
Semantic Scholar
Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?.
S. Verma, N. Mittmann, L. Bernard, M. Thompson +3 more
20093 citations
Semantic Scholar
Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)
R. Buckman, N. Wong, M. Clemons, S. Verma +6 more
20053 citations
Semantic Scholar
Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer
E. Eisenhauer, K. Pritchard, D. Perrault, S. Verma +1 more
1990Investigational new drugs3 citations
Semantic Scholar
Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
S. Verma, A. DeMichele, S. Loi, J. Ro +11 more
20162 citations
Semantic Scholar
Phase I study of oral menogaril administered daily for 14 consecutive days.
David J. Stewart, S. Aitken, S. Verma, Jean A. Maroun +4 more
1992Annals of Oncology2 citations Open access
Semantic Scholar
Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety
M. Cristofanilli, I. Bondarenko, J. Ro, S. Im +11 more
20161 citations
Semantic Scholar
Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD
J. Connors, P. Klimo, G. Adams, B. Burns +12 more
20161 citations
Semantic Scholar
Abstract P3-15-02: Underreporting of Myelotoxicity with Emerging Breast Cancer Regimens
T. Vandenberg, S. Verma, S. Loibl, J. Crawford +3 more
20101 citations
Semantic Scholar
Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment
J. Cortés, K. Gelmon, P. Fumoleau, A. Wardley +6 more
20081 citations
Semantic Scholar
O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)
S. Chan, A. Stopeck, A. Joy, S. Verma +6 more
20071 citations
Semantic Scholar
Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3
N. Harbeck, M. Colleoni, A. DeMichele, N. Turner +8 more
20170 citations
Semantic Scholar
A phase II study of docetaxel in chemotherapy-naõÈ ve patients with recurrent or metastatic adult soft tissue sarcoma
V. Bramwell, M. Blackstein, K. Bélanger, S. Verma +2 more
20140 citations
Semantic Scholar
Abstract B97: Vitamin D and mammographic density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial
Melanie Walker, H. Richardson, P. Goss, D. Jabs +16 more
2012Cancer Prevention Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Stewart×9
Invite
D. Stewart — researcher profile on SciRah
J. Maroun×8
Invite
J. Maroun — researcher profile on SciRah
E. Eisenhauer×8
Invite
E. Eisenhauer — researcher profile on SciRah
K. Gelmon×5
Invite
K. Gelmon — researcher profile on SciRah

×4

Invite

J. Pater — researcher profile on SciRah

Invite

H. Rugo — researcher profile on SciRah

Invite

A. Stopeck — researcher profile on SciRah

Invite

A. Joy — researcher profile on SciRah

Invite

S. Chan — researcher profile on SciRah

Invite

A. Lluch — researcher profile on SciRah

Invite

P. Bycott — researcher profile on SciRah

D. Soulières×4

Invite

D. Soulières — researcher profile on SciRah